ArticlePLoS pathogens2025
Profiling miRNA changes in Epstein-Barr virus lytic infection identifies a function for BZLF1 in upregulating miRNAs from the DLK1-DIO3 locus.
Article in PLoS pathogens, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Host serum-circulating flavivirus NS1 co-opts mosquito miRNA processing to suppress early immune defense.Nature communications · 2026Article
- The research progress of the synergistic effect of Epstein-Barr virus andFrontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Cellular and viral miRNAs are thought to play important roles in regulating Epstein-Barr virus (EBV) latent and lytic infections, however, to date, most studies have focussed on latent infections in B cells. To determine how cellular and viral miRNAs contribute to EBV lytic infection in epithelial cells, the main sites of lytic infection, we conducted miRNA-sequencing experiments in EBV-infected AGS gastric carcinoma cells, before and after reactivation to the lytic cycle, analysing both total miRNA and Ago2-associated miRNAs. We identified over 100 miRNAs whose association with Ago2 was affected upon EBV reactivation, most of which were due to changes in miRNA abundance. For EBV miRNAs, the most striking result was that the BHRF1 miRNAs, previously only reported to be expressed in B cells, were upregulated upon reactivation. The largest changes in cellular miRNAs upon EBV reactivation were increases in the abundance and Ago2-association of miR-409-3p, miR-381-3p and miR-370-3p, which appear to have pro-viral effects. In particular, inhibiting miR-409-3p reduced BZLF1 and other EBV lytic protein expression, at least in part through modulation of ZEB1. Interestingly, these miRNAs all originate from the DLK1-DIO3 locus (14q32.2 - 32.31), which encodes multiple lncRNAs. We showed that the lncRNAs MEG9, MIR381HG, and MEG8, from which miR-409-3p, miR-381-3p and miR-370-3p are derived, were also upregulated upon reactivation in AGS and nasopharyngeal carcinoma cells lines and occurred very early in the lytic cycle at the time of BZLF1 expression. In keeping with this timing, BZLF1 was sufficient to induce these lncRNAs dependent on its transactivation activity, and was detected at a key DLK1-DIO3 control element, consistent with a direct role in transcriptional activation. Therefore, we have identified a new role for BZFL1 in activating the expression of lncRNAs in the DLK1-DIO3 locus, resulting in induction of a subset of encoded miRNAs that promote lytic infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.